FRM
MDCO

Fox Run Management’s Medicines Co MDCO Stock Holding History

Fox Run Management’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-15,800
Closed -$585K – 981
2017
Q3 		$585K Buy
+15,800
New +$582K 0.17% 235
2016
Q2 		– Sell
-13,600
Closed -$432K – 730
2016
Q1 		$432K Buy
+13,600
New +$444K 0.29% 122

Other funds holding MDCO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
TBC
Three Bays Capital Boston, Massachusetts $848M AUM 7.41% 1-Year Est. Return
CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fox Run Management's MDCO Position: Q4 2017 in Review

Fox Run Management sold out of Medicines Co (MDCO) in Q4 2017, closing a stake of 15,800 shares — an estimated $585K sold.

Fox Run Management first reported a position in MDCO in Q1 2016 and held it in 2 quarters. The position peaked at $585K in Q3 2017. 202 funds tracked by Wall St. Rank hold MDCO as of Q4 2017.

  • Fox Run Management reported no remaining Medicines Co position as of Q4 2017 after selling out during the quarter.
  • Fox Run Management sold 15,800 Medicines Co shares in Q4 2017, an estimated $585K.
  • Fox Run Management first reported a position in Medicines Co in Q1 2016 and held it in 2 quarters.
  • Fox Run Management's Medicines Co position peaked at $585K in Q3 2017.
  • 202 funds tracked by Wall St. Rank held Medicines Co as of Q4 2017.

Based on Fox Run Management's 13F filing for Q4 2017, filed 18 Jan 2018.